Vetoquinol : A game-changing acquisition – target price raised to € 73 (vs € 65)
>Acquisition of two products (Drontal® / Profender®) for deworming cats and dogs - Last week, Vetoquinol announced that it had signed an agreement to acquire the European and UK rights to Profender® and Drontal® from Elanco for a total price of $ 140 million in cash. Profender® and Drontal® are de-worming drugs for dogs and cats, available in tablet or spot-on applications, and are expected to generate sales of close to € 45m.Under the terms of the agreement, the...V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.